Generic drug maker Mylan pulls a mini-Pfizer tax inversion

20140715-090314-32594503.jpg

Taking a page from Pfizer’s playbook, Mylan is buying Abbott Laboratories’ branded specialty and generics businesses in developed markets outside the U.S..  The $5B deal is structured to result in a tax inversion, with the newly formed merged company to be headquartered in the Netherlands.

“We see Mylan creating a platform for potential future acquisitions with this deal,” thanks to revenue from the Abbott products and a lowered tax rate of 20 to 21 percent in the first full year and high-teens later on, said JP Morgan analyst Chris Schott.

Abbott will continue to sell branded generics in developing markets.

This entry was posted in Pharmaceutical Industry and tagged , , , . Bookmark the permalink.

One Response to Generic drug maker Mylan pulls a mini-Pfizer tax inversion

  1. Pingback: AbbVie will buy Shire in another Pharma tax inversion strategy | MechanizedIntelligence

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s